Please login or register to print this page.

VIEW TAGS

Articles tagged ‘dronedarone’

October 30, 2015

Ranolazine and dronedarone in AF management: the HARMONY trial

Moderate dose ranolazine plus reduced dose dronedarone produces synergistic atrial fibrillation burden (AFB) reduction, with good tolerance/safety, according to results from the HARMONY trial published recently in Circulation: Arrhythmia and Electrophysiology.1

read more

April 30, 2014

Safety of dronedarone in routine clinical care

Dronedarone, as prescribed to atrial fibrillation (AF) patients in Sweden, has not exposed patients to increased risks of death or liver disease, according to a study published recently in the Journal of the American College of Cardiology.1

read more

September 27, 2012

Position statement on anti-arrhythmic drugs

The lack of clarity around the current use of anti-arrhythmic drugs (AADs) has led to a distinguished panel issuing a consensus position statement,1 published recently in the British Journal of Cardiology. The panel, led by Professor John Camm, gives evidence-based recommendations for the use of AADs in practice, particularly dronedarone, in light of recent changes to regulatory recommendations for this drug.

read more

February 7, 2012

Dronedarone: a new therapeutic option for atrial fibrillation

Lincolnshire cardiologists review the new antiarrhythmic agent, dronedarone, which is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF).

read more

December 1, 2011

PALLAS trial on dronedarone in AF now published

Dronedarone increases rates of serious vascular events in patients with permanent atrial fibrillation (AF) and additional cardiovascular risk factors, according to the PALLAS (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) trial1 published recently in the New England Journal of Medicine.

read more

August 2, 2011

DRONEDARONE SAFETY REVIEW TO INCLUDE CV EVENTS

The European Medicines Agency (EMA) is reviewing the cardiovascular (CV) risk associated with the anti-arrhythmic drug, dronedarone1 (Multaq®, Sanofi-Aventis), following the company’s recent discontinuation of the phase IIIb PALLAS (Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy) trial after it found increased CV events in those randomised to the drug.

read more

June 25, 2010

Atrial fibrillation, and hypertension

“Hypertension is the most prevalent risk factor leading to the development of atrial fibrillation (AF), the most common arrhythmia” according to Dr I Grundvold, University of Oslo.

read more

October 14, 2009

Multaq® (dronedarone) recommended 
for approval in the European Union

Sanofi-aventis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq® (dronedarone – 400mg Tablets).

read more

June 8, 2009

New heart failure data from ATHENA

Use of the antiarrhythmic drug dronedarone significantly reduced the risk of hospitalisation due to cardiovascular events or death in patients with paroxysmal or persistent atrial fibrillation or flutter in the ATHENA trial. New data are now available on trial patients with heart failure.

read more

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.